FMP

FMP

Enter

OCX - OncoCyte Corpor...

photo-url-https://images.financialmodelingprep.com/symbol/OCX.png

OncoCyte Corporation

OCX

NASDAQ

OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

2.08 USD

-0.04 (-1.92%)

Historical Prices

From:

To:

page loading card

About

ceo

Mr. Joshua Riggs

sector

Healthcare

industry

Biotechnology

exchange

NASDAQ

Description

OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Dete...

CIK

0001642380

ISIN

US68235C2061

CUSIP

68235C107

Address

15 Cushing

Phone

949 409 7600

Country

US

Employee

43

IPO Date

Dec 30, 2015

Financial Statement

-18M-15M-12M-9M-6M-3M03M2023 Q32023 Q42024 Q12024 Q22024 Q3RevenueNet Income

Earnings

-8-6-4-202022 Q42023 Q12023 Q22023 Q32023 Q42024 Q12024 Q22024 Q3EPS Consensus

OCX Financial Summary

CIK

0001642380

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

68235C107

ISIN

US68235C2061

Country

US

Price

2.08

Beta

1

Volume Avg.

80.53k

Market Cap

35.02M

Shares

-

52-Week

1.97-3.48

DCF

0.73

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-0.47

P/B

-

Website

https://oncocyte.com

Upgrades and Downgrades

We are unable to load the data!

fmp-logo

Latest OCX News

Parth Sanghvi

Jan 8, 2025

AI Oversight Proposal at Berkshire Hathaway

A shareholder of Berkshire Hathaway, Tulipshare, has submitted a resolution calling for the creation of an independent committee to oversee risks associated with artificial intelligence (AI) across Warren Buffett’s conglomerate. This initiative will be presented at Berkshire's annual meeting on May 3, highlighting concerns about the potential misuse of AI and its implications for privacy, data security, and human rights. Why It Matters Berkshire Hathaway, with its sprawling portfolio of co...

MCAP MediaWire

Aug 5, 2024

Oncocyte Announces August Investor Conferences Participation

IRVINE, Calif., August 5, 2024 — Oncocyte Corp.

MCAP MediaWire

Aug 1, 2024

Oncocyte to Announce Second Quarter 2024 Financial Results o...

Conference Call and Webcast on Thursday, August 8, 2024 at 2:00 p.m. PT / 5:00 p.m.

Seeking Alpha

May 15, 2024

OncoCyte Corporation (OCX) Q1 2024 Earnings Call Transcript

OncoCyte Corporation (NASDAQ:OCX ) Q1 2024 Earnings Conference Call May 15, 2024 4:30 PM ET Company Participants Jeff Ramson - Investor Relations Josh Riggs - President and Chief Executive Officer Conference Call Participants Mike Matson - Needham Mason Carrico - Stephens Operator Good afternoon. My name is Briana and I will be your conference operator today.

24/7 Wall Street

Apr 21, 2024

Buffett Grabs More of This Stock, Plus Other Notable Insider...

At the end of the previous week, the Oracle of Omaha yet again boosted his stake in a media giant's tracking stocks, even with shares still in retreat.

GlobeNewsWire

Apr 9, 2024

Oncocyte to Announce Fourth Quarter and Full Year 2024 Finan...

IRVINE, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, announced today that the company will release its fourth quarter and full year 2023 financial results on Friday, April 12, 2024, prior to the U.S. market open.

Seeking Alpha

Nov 9, 2023

OncoCyte Corporation (OCX) Q3 2023 Earnings Call Transcript

OncoCyte Corporation (NASDAQ:OCX ) Q3 2023 Earnings Conference Call November 9, 2023 8:00 AM ET Company Participants Stephanie Prince - IR, PCG Advisory Josh Riggs - President & CEO Conference Call Participants Mike Matson - Needham Jacob Krahenbuhl - Stephens Vidyun Bais - BTIG Operator Thank you for standing by. My name is Tamika and I will be your conference operator today.

GlobeNewsWire

Nov 3, 2023

Oncocyte to Announce Third Quarter 2023 Financial Results

Conference Call and Webcast on Thursday, November 9, 2023, at 5:00 a.m. PT / 8:00 a.m. ET Conference Call and Webcast on Thursday, November 9, 2023, at 5:00 a.m. PT / 8:00 a.m. ET

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep